NRAS and leukemia: An OCI‐AML3‐luc+ xenograft model was also utilized to measure the in vivo efficacy of midostaurin; OCI‐AML3‐luc+ cells express NRAS Q61L and carry an NPM1 gene mutation (type A) and the DNMT3A R882C mutation.32, 33 Midostaurin significantly lowered leukaemia burden as a function of bioluminescence in mice (P < .0001 for SKNO‐1‐luc+ xenograft model and P < .0001 for OCI‐AML3‐luc+ xenograft model) (Figures 4A,D and S2B), and significantly increased median survival (P < .0001 for SKNO‐1‐luc+ xenograft model and P < .0001 for OCI‐AML3‐luc+ xenograft model) (Figure 4B,E).